Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Barclays Maintains Equal-Weight on Adient, Lowers Price Target to $37

Barclays maintains Adient (NYSE:ADNT) with a Equal-Weight and lowers the price target from $45 to $37.

byBenzinga Newsdesk

April 7, 2022

1 minute read

Barclays maintains Adient (NYSE:ADNT) with a Equal-Weight and lowers the price target from $45 to $37.

Stifel Upgrades Nektar Therapeutics to Buy, Raises Price Target to $24

By Benzinga Newsdesk

Today, 11:29 PM

Stifel analyst Benjamin Burnett upgrades Nektar Therapeutics (NASDAQ:NKTR) from Hold to Buy and raises the price target from $22 to $24.

NKTR

News

‘Peloton seems to be back online as of around 12:35pm ET.’ -Pelo Buddy

By Benzinga Newsdesk

Today, 11:29 PM

https://www.twitter.com/i/status/1557406655993741319

PTON

Ayr Wellness’ Partner Wins Provisional Cultivation License In Connecticut

By Vuk Zdinjak

Today, 11:29 PM

Ayr Wellness Inc.

AYRWF

Legal
News

Aclaris Therapeutics Announces Proposed Settlement And Settlement Hearing Of Stockholder Derivative Action

By Benzinga Newsdesk

Today, 11:29 PM

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that a settlement hearing (the

ACRS

Barclays Maintains Equal-Weight on Adient, Lowers Price Target to $37

Related Posts

Stifel Upgrades Nektar Therapeutics to Buy, Raises Price Target to $24

‘Peloton seems to be back online as of around 12:35pm ET.’ -Pelo Buddy

Ayr Wellness’ Partner Wins Provisional Cultivation License In Connecticut

Aclaris Therapeutics Announces Proposed Settlement And Settlement Hearing Of Stockholder Derivative Action